行业日报 | 北交所 震荡微跌，创新药持续活跃，关注前沿新兴产业技术突破 2025 年 08 月 04 日 证券研究报告 北交所市场点评——20250801 核心结论 行情回顾：1）指数层面：8 月 1 日北证 A 股成交金额达 217.3 亿元，较上 一交易日减少 43.7 亿元，北证 50 指数收盘价为 1419.61，下跌 0.23%， PE_TTM 为 66.36 倍。北证专精特新指数收盘价为 2425.87，下跌 0.29%； 2）个股层面：当日北交所 269 家公司中 158 家上涨，6 家平盘，105 家下 跌。其中涨幅前五的个股分别为：生物谷（23.2%）、立方控股（11.1%）、 大唐药业（10.2%）、讯安科技（9.7%）、戈碧迦（8.5%）；跌幅前五的个 股分别为：鼎佳精密（-14.6%）、三元基因（-9.5%）、方盛股份（-9.1%）、 云创数据（-6.4%）、明阳科技（-5.6%）。 新闻汇总：1）英伟达 800V 架构重塑产业链 AIDC 供电效率将迎变革：英 伟达最新 800V 架构供应商名单曝光，英诺赛科入选；公司拥有全球最大的 8 英寸硅基氮化镓晶圆的生产能力；未来 AI 数 ...

Group 1 - The company demonstrated resilience and steady development despite the overall downturn in the industry, achieving an operating income of 416 million yuan and a net profit of 85.64 million yuan, with a gross margin of 78.80% [1] - The business layout is centered around neuro and digestive system drugs, with strong sales from products like cytidine diphosphate sodium tablets, which serve as a stabilizing force for the company's performance [1] - The company significantly increased its R&D investment, with R&D expenses accounting for 9.55% of revenue and capitalized R&D expenditures rising to 73.66%, indicating a robust conversion of research outcomes [1] Group 2 - Continuous innovation in R&D is providing strong momentum for the company's sustainable development, with expectations for future performance to reach new heights [2] - The company achieved new milestones in market expansion, with products like pregabalin oral solution selected in the 10th batch of national drug centralized procurement, and rapid sales growth for new and existing products [2] - The company plans to maintain its innovation-driven development strategy, enhance core competitiveness, and strategically invest to expand business areas and market space, contributing to the healthcare sector [2]